inquilinu
limosu
aerob
rod
predomin
cultur
patient
cystic
fibrosi
cf
thought
soil
bacterium
littl
known
habitat
reservoir
organ
often
pseudomona
aeruginosa
pa
difficult
treat
given
extens
resist
pattern
limosu
pathogen
poorli
understood
multipl
report
identifi
organ
cultur
rdna
sequenc
yet
relev
remain
uncertain
given
report
rang
deterior
associ
isol
clinic
impact
describ
pediatr
patient
isol
abund
limosu
concert
mycobacterium
ntm
common
pathogen
patient
symptom
sever
progress
resolv
treatment
regimen
optim
limosu
patient
male
cf
g
pancreat
insuffici
present
chest
pain
fever
patient
chronic
colon
staphylococcu
aureu
mrsa
success
complet
erad
therapi
pa
isol
month
prior
grown
haemophilu
speci
yeast
exophilala
dermatitidi
stenotrophomona
maltophilia
year
prior
present
initi
visit
outsid
emerg
depart
diagnos
pneumonia
given
intramuscular
ceftriaxon
follow
oral
cephalosporin
follow
pulmonologist
prompt
chang
given
histori
mrsa
colon
patient
improv
present
day
later
fever
cough
chest
pain
right
middl
lobe
rml
infiltr
chest
percent
predict
forc
expiratori
volum
one
second
declin
baselin
prompt
admiss
bronchoscopybronchoalveolar
lavag
bal
perform
rare
mycobacteria
ntm
isol
first
time
along
maltophilia
new
rod
sent
cdc
identif
ultim
identifi
limosu
treat
symptomat
role
unclear
patient
antibiot
regimen
chang
ceftarolin
voriconazol
better
cover
chronic
colon
mrsa
previou
pathogen
treat
day
improv
continu
symptom
baselin
two
week
later
patient
improv
howev
fatigu
cough
weight
loss
persist
decreas
concern
treatment
previou
aspergillu
inadequ
voriconazol
resum
return
clinic
week
later
patient
return
ongo
fatigu
chest
pain
short
breath
declin
prompt
readmiss
chest
demonstr
new
densiti
right
lung
base
right
hilar
peribronchi
thicken
prompt
chest
ct
show
nodular
peripher
consolid
lower
lobe
consolid
rml
bronchoscopi
perform
show
rare
ntm
abund
limosu
identifi
state
lab
coronaviru
due
presumpt
worsen
symptom
primarili
due
coronaviru
treat
antibiot
discharg
home
allerg
bronchopulmonari
aspergillosi
abpa
consid
throughout
time
howev
reassur
ige
eosinophil
count
nonspecif
ct
scan
made
diagnosi
unlik
patient
fever
headach
fatigu
poor
appetit
continu
one
week
discharg
start
levofloxacin
inhal
gentamicin
address
ongo
symptom
within
day
symptom
progress
night
sweat
exercis
intoler
increas
sputum
product
chest
pain
prompt
readmiss
attempt
initi
aggress
treatment
start
empir
moxifloxacin
amikacin
azithromycin
base
publish
limosu
ntm
antibiot
regimen
continu
worsen
continu
night
sweat
declin
meropenem
ad
addit
coverag
recommend
infecti
diseas
consult
given
limosu
grown
abund
multipl
occas
ntm
growth
rare
becam
focu
treatment
optim
antibiot
regimen
design
base
upon
report
literatur
identifi
antimicrobi
patient
place
meropenem
amikacin
ciprofloxacin
limosu
clindamycin
given
histori
mrsa
colon
day
regimen
patient
symptomat
improv
patient
discharg
home
iv
amikacin
meropenem
oral
ciprofloxacin
limosu
treatment
complet
total
week
clindamycin
total
week
cours
patient
fever
night
sweat
chest
pain
resolv
rose
time
cultur
ntm
identifi
mycobacterium
intracellular
mac
patient
subsequ
start
azithromycin
ethambutol
rifampin
given
patient
cours
ntm
outcom
center
subsequ
spirometri
reveal
stabl
without
isol
limosu
ntm
subsequ
throat
swab
sputum
case
demonstr
challeng
treat
cf
patient
multifactori
bacteri
infect
potenti
pathogen
limosu
patient
chronic
isol
mrsa
upper
airway
previous
mild
exacerb
respond
mrsa
treatment
yet
improv
initi
treatment
usual
cf
pathogen
patient
repeatedli
isol
larg
amount
limosu
bal
signific
improv
aggress
treatment
target
organ
initi
figur
ill
began
prior
isol
possibl
limosu
contribut
earlier
given
difficulti
identif
publish
evid
immun
respons
inquilinu
prior
cultur
fulli
rule
influenc
mrsa
mac
patient
cours
notabl
never
isol
mrsa
lower
airway
period
treatment
direct
toward
mac
improv
prolong
cours
target
limosu
case
young
cf
patient
multipl
sourc
infect
demonstr
complex
cf
exacerb
support
notion
limosu
emerg
pathogen
patient
clinic
cours
demonstr
need
antibiot
coverag
limosu
reinforc
potenti
pathogen
develop
treatment
plan
author
declar
conflict
interest
